Fiduciary Trust Co Purchases 1,323 Shares of Amgen Inc. (NASDAQ:AMGN)

Fiduciary Trust Co boosted its position in Amgen Inc. (NASDAQ:AMGN) by 2.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 53,295 shares of the medical research company’s stock after acquiring an additional 1,323 shares during the period. Fiduciary Trust Co’s holdings in Amgen were worth $17,172,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Amgen by 18.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 611,410 shares of the medical research company’s stock valued at $197,002,000 after purchasing an additional 94,524 shares during the period. CreativeOne Wealth LLC boosted its position in shares of Amgen by 29.4% during the third quarter. CreativeOne Wealth LLC now owns 10,392 shares of the medical research company’s stock worth $3,348,000 after purchasing an additional 2,364 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Amgen by 573.3% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 355,872 shares of the medical research company’s stock valued at $114,666,000 after buying an additional 303,016 shares during the period. Townsquare Capital LLC increased its position in shares of Amgen by 3.1% in the 3rd quarter. Townsquare Capital LLC now owns 28,794 shares of the medical research company’s stock valued at $9,278,000 after buying an additional 855 shares in the last quarter. Finally, Shum Financial Group Inc. acquired a new stake in Amgen during the 3rd quarter worth $352,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AMGN. Dbs Bank raised Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Citigroup cut their price target on shares of Amgen from $335.00 to $310.00 in a research note on Wednesday. Royal Bank of Canada lowered their price objective on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research report on Wednesday. Barclays upped their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Finally, William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $323.05.

Amgen Trading Up 0.0 %

Amgen stock opened at $280.07 on Thursday. The stock has a 50-day simple moving average of $313.58 and a 200 day simple moving average of $317.57. The stock has a market capitalization of $150.55 billion, a P/E ratio of 35.86, a PEG ratio of 2.62 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52 week low of $257.80 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the previous year, the company posted $4.96 EPS. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. Analysts expect that Amgen Inc. will post 19.52 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 3.21%. Amgen’s dividend payout ratio is currently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.